LiverMultiScan - the evidence is here in Boston
Thanks to advances in magnetic resonance imaging, quality control and artificial intelligence, the clinical evidence is now available to identify patients with liver disease painlessly, monitor treatment response and predict patient outcomes. Many of these advances were pioneered by Perspectum, but we are not alone in our efforts to help patients with MASH/MAFLD; the American Association for the Study of Liver Diseases (AASLD) is a professional community aligned around the?same goal.
While treatment for diagnosed patients still mostly consists of lifestyle choices, and some limited?pharmacological interventions, patients and physicians alike are eagerly anticipating the approval of?new medicines that hold tremendous promise for patients with early-to-late liver disease. Advocates hope these treatments will be available in the first half of 2024, if not sooner. I feel everyone is excited?to see what we learn in the next three days about their timing. What’s more, the success of?GLP-1?agonists in supporting significant weight loss and the attendant changes in liver tissue characterisation will force an important discussion about how medicine measures and defines resolution of 'fatty liver disease'.
?I look forward to attending The Liver Meeting this week as we work to advance imaging and anticipate the potential arrival of new therapeutics. #TLM23 always provides a great forum to discuss critical issues. Perspectum is presenting six abstracts and one poster, hosting an interactive 45 minute product theater (Monday, Nov. 13th, 3:45 pm ET at Product Theater 1, Exbitition Hall B) and sharing our insights into our efforts at our Booth (B1107).
I hope you’re as excited about it as I am.
banjo